First diagnostic saliva test for malaria to launch
ERADA Technology Alliance Ltd (ERADA) has announced the imminent launch of a ground-breaking diagnostic saliva test for malaria. The saliva-based diagnostic tool, to be marketed...
Lynparza is approved by FDA for advanced ovarian cancer
AstraZeneca and MSD announce Lynparza is approved by FDA for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. AstraZeneca and MSD...
Dengvaxia ® vaccine approved for dengue prevention in Europe
The European Commission has granted marketing authorisation for Dengvaxia ®, Sanofi's dengue vaccine. The marketing authorisation follows the October 18, 2018, recommendation by the European...
Almirall releases results of onychomycosis phase III trial of P-3058
Almirall announces that the pivotal study for P-3058 has met the primary endpoint in an onychomycosis phase III trial. Almirall, S.A (ALM) has announced that...
Recipharm explores ending operations in Ashton-under-Lyne facility
Recipharm is to initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK. The decision to initiate...
BREAKING NEWS: GSK and Pfizer to merge consumer healthcare
GSK and Pfizer to merge consumer healthcare in a Joint Venture announced this morning. This lays the foundation for separation of GSK to create...
Social & commercial network to enhance health innovation
University of Brighton researchers are joining forces with entrepreneurs and community groups to turn Brighton and Hove into a focal point for health innovation...
BMS & Boston Medical Center announce research collaboration
BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
EC approves KEYTRUDA® as adjuvant therapy
MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...
Rubraca receives CHMP positive opinion for ovarian cancer
Clovis Oncology announces that Rubraca receives CHMP positive opinion recommending an additional indication for ovarian cancer. Clovis Oncology, Inc. has announced that the European Unions (EU) European...
Latest articles
IMBRUVICA® misses primary endpoint in pancreatic cancer trial
AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer. AbbVie, a research-based global biopharmaceutical company,...
Star Europe’s Amsterdam office off to positive start
Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
EC approves Vertex’s ORKAMBI® for cystic fibrosis patients
Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients. The European Commission has granted approval...